Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer

ECU Author/Contributor (non-ECU co-authors, if there are any, appear on document)

Shravanti,Laks,Shachar,Naqash,Abdul Rafeh,Bulumulle,Anushi,Zervos,Emmanuel,Muzaffar,Ma Macherla (Creator)

Institution

East Carolina University (ECU )

Web Site: http://www.ecu.edu/lib/

Abstract: Immune checkpoint blockade (ICB) with programmed cell death protein-1(PD-1)/programmed death ligand -1(PD-L1) antibodies has revolutionized the management of several cancers, especially non-small cell lung cancer, melanoma, urothelial, and renal cancer. Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers associated with high morbidity and mortality. Based on available data, it"s obvious that ICB has limited success in PDACs, which can be explained by the low immunogenicity and immunosuppressive tumor microenvironment of these tumors. In this review article, we focus on PD-L1 expression and microsatellite instability (MSI) in PDAC, and their roles as prognostic and predictive markers. We also discuss data supporting combination therapies to augment cancer immunity cycle. Combining anti-PD-1/PD-L1 agents with other modalities such as vaccines, chemotherapy, and radiation could potentially overcome resistance patterns and increase immune responsiveness in PDAC

Additional Information

Publication

Other

Language: English

Date: 2018

Keywords

pancreatic adenocarcinoma; programmed death ligand; microsatellite instability

Email this document to